Zhejiang New Code Biopharmaceutical

NewCode Biopharmaceutical is a clinical-stage biotechnology company headquartered in Huzhou, China, specializing in the development of next-generation antibody-drug conjugates (ADCs). The company utilizes a proprietary site-specific conjugation platform involving unnatural amino acids to create homogeneous and stable therapeutic candidates. Its lead program, ARX788, is a HER2-targeted ADC currently in Phase 3 clinical trials for breast and gastric cancers. NewCode Biopharmaceutical operates through a strategic partnership with Ambrx, from which it licensed several key ADC assets for development and commercialization in the Greater China region.